Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100

In the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL (degludec) was superior to insulin glargine 100 units/mL (glargine U100) with respect to the rates of severe (DEVOTE; across trial) and overall symptomatic (SWITCH 2; during the maintenance period of the trial) hypoglycaemia in individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexopoulos, Anastasia‐Stefania, Andersen, Andreas, Donatsky, Anders Meller, Gowda, Amoolya, Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286333/
https://www.ncbi.nlm.nih.gov/pubmed/33830626
http://dx.doi.org/10.1111/dom.14397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286333/
https://www.ncbi.nlm.nih.gov/pubmed/33830626
http://dx.doi.org/10.1111/dom.14397

Ejemplares similares